Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol Cyclo Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced a positive outcome from its recent Type C meeting with the U.S. Food and Drug Administration (FDA), held on Thursday, December 14, 2023 to discuss a full data review of the Company’s Trappsol Cyclo clinical development program to date and proposed strategies for the statistical analysis for the ongoing pivotal Phase 3 study, TransportNPC, in order to enable a patient population lacking available therapies to have earlier access to a potentially efficacious product with an acceptable safety profile.

N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, added, “We view our Type C meeting with FDA as a catalytic and transformational milestone for our ongoing pivotal Phase 3 NPC program. By working closely and in alignment with FDA, I am confident our leadership team has positioned Cyclo Therapeutics for rapid continued advancement and has established the appropriate path to generate the data required to successfully drive our TransportNPC study across the finish line.”

In summary, the Company’s clinical data (NCT02939547, NCT03893071 and NCT02912793) provided suggestive evidence, based on individual patient data, of potential therapeutic benefit which may be observed at or before 48 weeks of treatment. Given the significant unmet need within this Orphan Disease and the lack of available effective pharmacotherapy, and that aggregate clinical and nonclinical data argue for a potentially clinically relevant therapeutic effect, the FDA aligned with Cyclo Therapeutics’ proposal to continue with the agreed upon Phase 3 96-week study, but change the timing of the planned comparative interim analysis to execute data readout in Q1 2025.

“The FDA feedback we received allows us to proceed as planned to meet our full enrollment goals as well as our regulatory and corporate objectives to bring a potential treatment option to this underserved patient community as quickly as possible. We look forward to implementing these changes and to our future pre-NDA meeting with the FDA as we continue to execute across all aspects of our drug development program,” stated Michael Lisjak, Chief Regulatory Officer and Senior Vice President of Business Development for Cyclo Therapeutics.